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ABSTRACT
Basal-like breast cancers (BLBCs) are aggressive breast cancers associated 
with poor survival. Defining the key drivers of BLBC growth will allow identification 
of molecules for targeted therapy. In this study, we performed a primary screen 
integrating multiple assays that compare transcription factor expression and activity 
in BLBC and non-BLBC at the RNA, DNA, and protein levels. This integrated screen 
identified 33 transcription factors that were elevated in BLBC in multiple assays 
comparing mRNA expression, DNA cis-element sequences, or protein DNA-binding 
activity. In a secondary screen to identify transcription factors critical for BLBC cell 
growth, 8 of the 33 candidate transcription factors (TFs) were found to be necessary 
for growth in at least two of three BLBC cell lines. Of these 8 transcription factors, 
SOX11 was the only transcription factor required for BLBC growth, but not for growth 
of non-BLBC cells. Our studies demonstrate that SOX11 is a critical regulator of 
multiple BLBC phenotypes, including growth, migration, invasion, and expression of 
signature BLBC genes. High SOX11 expression was also found to be an independent 
prognostic indicator of poor survival in women with breast cancer. These results 
identify SOX11 as a potential target for the treatment of BLBC, the most aggressive 
form of breast cancer.
INTRODUCTION
Breast cancer is a heterogeneous disease that can 
be divided into clinically defined subtypes including 
estrogen receptor (ER)-positive, HER2-positive, and 
triple-negative breast cancer (TNBC, which lack ER, 
progesterone receptor (PR) and HER2), or molecularly 
defined subtypes including luminal A, luminal B, 
HER2-enriched and basal-like breast cancer (BLBC). 
Identifying critical regulators specific to these subtypes 
has led to the development of targeted therapies; 
particularly, endocrine therapy for ER-positive breast 
cancer patients [1], and HER2-targeting therapies for 
patients with HER2-amplified tumors [2]. As TNBCs 
lack ER, PR, and HER2, they do not respond to these 
available targeted therapies. Furthermore, key regulators 
of TNBC tumor growth have not been defined. Genomic 
studies of TNBC have revealed that approximately 75% 
of TNBC can be molecularly defined as BLBC by mRNA 
expression [3]. Additionally, BLBCs characteristically 
overexpress proliferation genes and have TP53 gene 
mutations [3], which contribute to the aggressive growth 
and poor survival of BLBC [4]. To develop effective 
targeted therapies for this aggressive type of breast 
cancer, a better understanding of the key regulators of 
BLBC is required.
Microarray expression studies are useful in 
defining distinct breast cancer subtypes. The contrasting 
mRNA expression in BLBC versus other breast cancer 
subtypes suggests that transcription factors (TFs) may 
be critical for the development and progression of 
these breast cancer subtypes. The important role of 
transcription factors in promoting breast tumor growth 
is seen in the luminal subtype which is predominantly 
defined by the activity of the ER-alpha transcription 
factor.
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In this study we hypothesized that specific 
transcription factors are critical for BLBC growth and 
maintenance of BLBC phenotypes. We utilized an 
integrated genomic screen to identify transcription factors 
overexpressed or active in BLBC compared to non-BLBC. 
For this study, we used three independent approaches in 
our primary screen to identify critical transcription factors 
by determining the: (1) transcription factors differentially 
expressed at the mRNA level in TNBC compared with 
non-TNBC tumors; (2) transcription factor DNA motifs 
overrepresented among the promoters of selected BLBC 
genes; and (3) transcription factor motifs which are more 
highly bound by nuclear proteins present in BLBC versus 
non-BLBC cells. We then integrated the results of these 
three independent approaches and identified 33 transcription 
factors that are highly active in BLBCs. We then performed 
a secondary screen to discover whether the individual 
transcription factors identified in our primary screen are 
critical for growth of BLBC cells, and found that inhibition 
of 8 of the 33 candidates resulted in reduced growth 
of at least two of three BLBC cell lines tested. Of the 8 
transcription factors critical for BLBC growth, inhibition 
of SOX11 had the most BLBC-specific effect, suppressing 
growth in all three BLBC cell lines, while minimally 
affecting growth of three non-BLBC cell lines. Further 
evaluation of SOX11 demonstrated SOX11 is critical for 
multiple BLBC phenotypes including invasion, migration, 
and expression of key BLBC genes. We also found that high 
SOX11 expression is an independent prognostic marker of 
poor survival in women with breast cancer. Taken together, 
these results identify SOX11 as a critical regulator of 
gene expression in BLBC and a promising target for the 
treatment of these aggressive breast cancers.
RESULTS
RNA-, DNA-, and protein-based assays identify 
transcription factors highly expressed or active 
in basal-like breast cancer
To identify transcription factors highly active in 
BLBCs, we integrated in silico and in vitro analyses of 
mRNA expression, DNA sequence, and protein activity 
(Figure 1). We used mRNA expression to distinguish the 
set of transcription factors that are more highly expressed 
in TNBC versus non-TNBC tumors,. We then used DNA 
sequences from promoters of genes highly expressed 
in BLBC to identify transcription factor motifs that are 
overrepresented in BLBC gene promoters. Finally, we 
tested the DNA-binding activity of nuclear proteins from 
BLBC and non-BLBC cell lines to identify transcription 
factor motifs that are more highly bound by proteins from 
BLBC cells as compared to proteins from non-BLBC cells.
For our RNA-based screen (Figure 1A), we focused 
on a set of 702 genes whose proteins have been shown 
to have sequence-specific DNA-binding activity in 
mammalian cells [5], and examined mRNA expression 
in TNBC and non-TNBC breast cancer across 15 
human breast tumor datasets. As described in Materials 
and Methods, we used OncomineTM (oncomine.com, 
Compendia Bioscience, Ann Arbor, MI) to perform 
a median-rank-based meta-analysis of differential 
expression in TNBC vs. non-TNBC. The p-values of each 
differentially expressed gene in each of the 15 datasets 
are shown using a colorimetric scale in Figure 1D. The 
genes were ranked using the p-value from the dataset that 
had the median gene rank across all datasets. The p-value 
of the median ranked gene is shown colorimetrically in 
the right column labeled “Median Rank p-value”. Of 
the 702 transcription factors queried, we identified 132 
transcription factors that are significantly overexpressed 
(median rank p-value <0.05) in TNBC compared to non-
TNBC tumors. The top 25 genes are shown in Figure 
1D; the complete set of significant genes is listed in 
Supplementary Table S1.
We next used the frequency of transcription factor 
DNA binding motifs present in promoters of genes highly 
expressed in BLBC tumors to identify the transcription 
factors that regulate the expression of these BLBC genes 
(Figure 1B). First, we defined a 117-gene BLBC gene set 
by identifying genes which were more highly expressed 
in BLBC compared to non-BLBC (with a p-value <0.01) 
in three previously published, independent breast tumor 
microarrays [6–8] (Supplementary Table S2). Then, using 
the program CORE_TF [9], we compared the frequencies 
of individual transcription factor binding motifs within the 
promoter (defined as -1kb through exon 1) of each gene 
in the 117-gene BLBC set, as well as 1500 randomly-
selected genes that were not significantly overexpressed in 
BLBC. We identified 95 unique position weight matrices 
significantly over-represented in promoters of the BLBC 
gene set with a p-value <0.05 using Fisher’s Exact Test 
(the 25 most significantly different motifs are shown in 
Figure 1E; the complete results for significantly over-
represented motifs is shown in Supplementary Table S3). 
We then used TRANSFAC annotations and published 
literature to identify 109 unique transcription factor genes 
that recognize the motifs overrepresented in BLBC gene 
promoters (Supplementary Table S4).
We conducted a third assay to identify 
transcription factor proteins that are more active in 
BLBC versus non-BLBC cell lines by comparing the 
ability of nuclear proteins from BLBC and non-BLBC 
cell lines to bind specific DNA response elements. We 
extracted nuclear protein from 4 BLBC and 4 non-
BLBC cell lines and investigated in vitro binding of 
these proteins to specific DNA oligonucleotide motifs 
to measure DNA-binding activity using transcription 
factor protein DNA-binding arrays as described in 
Materials and Methods (and outlined in Figure 1C). 
Comparing the relative binding of each motif by 
BLBC and non-BLBC proteins, we used both fold-
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change (>1.4) and p-value (<0.05) cutoff criteria to 
select transcription factor motifs that had significantly 
increased binding by protein from BLBC cells 
(Figure 1F). In these experiments, 11 transcription 
factor motifs met these criteria, having higher binding 
by BLBC cells (Figure 1G, full results in Supplementary 
Figure S1). Using TRANSFAC and published literature, 
we identified 25 unique transcription factor genes 
which bind the identified transcription factor motifs 
(Supplementary Table S5).
Integration of the three independent assays 
identifies 33 candidate basal-like breast cancer 
transcription factors
We next integrated the results of the mRNA, DNA, 
and protein assays from our primary screen to select 
the set of transcription factors to test in our secondary 
screen. transcription factors identified in two of the three 
primary assays were selected for further study (Figure 
2). Two transcription factors were identified by all three 
Figure 1: Independent assays of RNA, DNA and protein identify transcription factors increased in BLBC. Screening 
methods used, and number of significant hits identified in A. RNA expression screen, B. DNA motif screen, and C. protein DNA-binding 
screen. D. Heatmap of p-values for 25 most significantly overexpressed transcription factors in TNBC as compared to non-TNBC across 
15 datasets, ordered by median rank p-value. E. Top 25 DNA motifs overrepresented in promoters of BLBC genes. F. Results of protein-
DNA array by fold change and p-value, with the red box indicating motifs with a fold change >1.4 and p-value <0.05 in BLBC compared 
to non-BLBC cells, with individual plots from those candidates in G.
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assays: signal transducer and activator of transcription 1 
(STAT1) and peroxisome proliferator-activated receptor 
alpha (PPARA). An additional 26 transcription factors 
were identified in both the mRNA expression and DNA-
motif frequency screens, while 5 transcription factors were 
identified in both the mRNA expression and protein-bound 
motif assays. Thus, a total of 33 transcription factors were 
identified by at least two of the screening methods. We 
then investigated each of these 33 transcription factors 
in our secondary screen to determine which of these 
transcription factors are required for the growth of BLBC 
cells.
Secondary screen to identify transcription 
factors critical for basal-like breast cancer 
growth
Our primary integrated genomic screen identified 33 
transcription factors highly expressed and active in BLBC 
cells, but it did not specifically select for growth regulating 
transcription factors. Therefore, in our secondary screen 
we identified those transcription factors critical for the 
growth of BLBC cells. For this screen, we used pools of 3 
siRNAs to decrease expression of 29 of the 33 candidate 
transcription factors in a set of BLBC and non-BLBC cell 
lines (Table 1) (4 transcription factors were excluded from 
the secondary screen; we were unable to design effective 
qRT-PCR assays for 2, and 2 did not exhibit reduced 
mRNA following knockdown). For the remaining 29 
transcription factors, siRNA knockdown was confirmed 
in MDA-MB-468 cells (data not shown).
As expected, many of the candidate transcription 
factors were not required for growth, or were critical 
in only a single BLBC cell line, including the two 
transcription factors identified by all three screens, 
PPARA and STAT1. These transcription factors may be 
important regulators of other basal-like phenotypes. For 
8 of the candidate transcription factors, siRNA inhibition 
suppressed growth by at least one-third (33%) compared 
to non-targeting siLuc control siRNA in at least two of 
three BLBC cell lines. Of these 8 critical BLBC growth 
regulators, three (MYC, CDC5L, and NFKB2) were also 
critical for growth in two of three non-BLBC cell lines 
tested, demonstrating that these factors are most likely 
general growth regulators, not uniquely specific to BLBC. 
An additional four transcription factors (ATF4, FOXM1, 
FOSL2, and TFDP1) were moderately specific for growth 
of BLBC, with siRNA causing growth reduction in at 
least two BLBC cell lines and only one non-BLBC cell 
lines. MYC [10] and FOXM1 [3, 11] have been previously 
associated with breast cancer growth. The identification 
of these known growth regulating transcription factors 
validates our integrated screening strategy and serves as 
a positive control for the secondary growth screen. Of 
the 8 growth regulating factors, SOX11 demonstrated the 
most BLBC specificity, with siRNA to SOX11 resulting in 
reduced growth for all three BLBC cell lines, and minimal 
growth inhibition in three non-BLBC cell lines.
Figure 2: Integration of independent assays identifies 33 candidate BLBC transcription factors. Comparison of mRNA 
expression, DNA sequence motif, and protein-bound element screening results identified transcription factors that were found in multiple 
assays. A list of transcription factors identified in both the mRNA expression and protein-binding screen (but not DNA-motif) is outlined 
in purple. A list of transcription factors identified in both mRNA expression and DNA-motif screens (but not protein DNA-binding) is 
outlined in orange. A list of transcription factors identified in all three screens is outlined in black.
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SOX11 expression is elevated in basal-like and 
HER2 breast tumors
SOX11 was one of the transcription factors found 
to have higher expression in TNBC compared to non-
TNBC (Supplementary Table S1), but a detailed analysis 
of SOX11 expression in normal breast and breast cancer 
subtypes had not been performed. In a large breast cancer 
dataset, SOX11 mRNA levels are significantly elevated 
in each of the intrinsic breast cancer subtypes compared 
Table 1: Results of siRNA growth screen of candidate basal-like transcription factors
siRNA BLBC Non-BLBC
BT20 HCC1143 MDA468 MCF7 T47D ZR751
SOX11 51 ± 8 61 ± 10 40 ± 7 96 ± 4 72 ± 3 95 ± 10
ATF4 65 ± 19 49 ± 17 47 ± 2 70 ± 7 38 ± 1 78 ± 9
FOXM1 34 ± 5 70 ± 17 52 ± 6 77 ± 11 66 ± 8 105 ± 21
FOSL2 52 ± 11 53 ± 12 71 ± 27 93 ± 21 60 ± 35 84 ± 12
TFDP1 56 ± 11 34 ± 14 103 ± 16 45 ± 8 119 ± 89 123 ± 14
MYC 40 ± 5 34 ± 6 71 ± 11 76 ± 15 42 ± 3 59 ± 14
CDC5L 36 ± 5 25 ± 13 25 ± 9 68 ± 2 30 ± 3 34 ± 6
NFKB2 41 ± 7 23 ± 7 4 ± 4 14 ± 1 28 ± 2 91 ± 14
E2F2 44 ± 11 68 ± 12 79 ± 16 55 ± 15 62 ± 46 77 ± 9
KLF5 74 ± 3 71 ± 7 55 ± 5 57 ± 16 79 ± 11 109 ± 8
RXRB 36 ± 5 70 ± 8 93 ± 21 87 ± 33 28 ± 4 68 ± 9
SOX6 55 ± 7 70 ± 10 89 ± 9 100 ± 5 43 ± 1 76 ± 6
E2F5 66 ± 17 107 ± 31 173 ± 9 140 ± 10 49 ± 3 120 ± 10
NFYA 70 ± 6 74 ± 11 65 ± 6 83 ± 29 101 ± 7 62 ± 11
CEBPB 98 ± 18 71 ± 15 56 ± 8 67 ± 5 76 ± 21 38 ± 12
CEBPG 70 ± 4 86 ± 19 55 ± 4 103 ± 5 96 ± 9 82 ± 6
SOX4 76 ± 17 61 ± 8 90 ± 9 80 ± 10 71 ± 11 91 ± 5
KLF11 122 ± 32 60 ± 13 88 ± 14 88 ± 9 77 ± 19 106 ± 5
KLF13 65 ± 7 87 ± 4 83 ± 20 100 ± 7 81 ± 10 90 ± 7
NFYC 73 ± 12 72 ± 7 78 ± 8 105 ± 13 110 ± 40 39 ± 12
SOX9 91 ± 15 94 ± 15 99 ± 7 108 ± 18 66 ± 10 64 ± 7
SOX10 102 ± 24 81 ± 16 132 ± 9 154 ± 16 32 ± 4 116 ± 9
CREB5 84 ± 15 70 ± 26 99 ± 13 111 ± 14 33 ± 1 117 ± 6
PPARD 76 ± 17 67 ± 9 118 ± 13 88 ± 22 56 ± 8 78 ± 13
ARNT 131 ± 36 153 ± 29 138 ± 12 132 ± 9 22 ± 2 105 ± 12
STAT1 108 ± 22 113 ± 7 80 ± 14 83 ± 6 56 ± 8 93 ± 16
PPARA 103 ± 12 131 ± 26 107 ± 5 94 ± 7 97 ± 10 81 ± 7
KLF12 119 ± 13 79 ± 2 91 ± 2 96 ± 10 79 ± 13 107 ± 6
E2F3 76 ± 5 138 ± 17 107 ± 11 83 ± 10 85 ± 11 91 ± 27
Growth relative 
to siLuc after 6 
days
< 33% 33 - 66% > 66%
Growth of BLBC and non-BLBC breast cancer cell lines following siRNA inhibition of candidate BLBC transcription 
factors. Numbers indicate percent growth after 6 days relative to non-targeting siLuc control ± standard deviation.
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to normal breast samples. Additionally, SOX11 levels in 
HER2 and BLBC subtypes are significantly higher than 
tumors of the luminal A, luminal B, normal-like, and 
claudin-low subtypes (Figure 3A and Supplementary 
Figure S2). While the majority of TNBC breast tumors 
are classified as BLBC, the heterogeneity of TNBC has 
led to additional subtypes within TNBC. Using previously 
published breast cancer expression data [12], we evaluated 
SOX11 levels in the TNBC subtypes defined by Lehmann 
et al. [13] and Burstein et al. [12]. SOX11 levels did not 
significantly differ between the Lehmann defined groups, 
whereas, within the Burstein defined groups, SOX11 was 
significantly higher in the basal-like immune-activated 
(BLIA) and basal-like immune suppressed (BLIS) groups 
compared to other TNBC subtypes (Supplementary 
Figure S2).
Several potential mechanisms may be responsible 
for the elevated SOX11 expression in breast cancer 
compared to normal breast tissue. One possibility is that 
SOX11 is methylated in normal adult mammary cells, and 
becomes hypomethylated in cancer, particularly Her2-
positive and basal-like breast cancers. Hypomethylation 
of oncogenic genes has been associated with many 
cancer types [14]; and methylation has been shown to 
be associated with SOX11 expression in hematopoietic 
and solid tumors [15, 16]. Therefore, we investigated 
methylation of CpG sites near the SOX11 genomic 
location. Using methylation and expression data from 
normal breast samples and breast tumors collected in 
TCGA, we found that while SOX11 expression is kept 
low in normal breast samples, CpG sites near SOX11 
are not highly methylated (Figure 3 and Supplementary 
Figure S3). Methylation at the same site in basal-like 
breast tumors was not significantly altered; however, 
expression is significantly increased. Interestingly, 
though most luminal A and luminal B tumors maintain 
SOX11 expression levels comparable, or slightly higher 
than normal breast cells, there is a significant increase in 
methylation levels of CpG sites near SOX11 in these types 
of tumors (Figure 3 and Supplementary Figure S3).
SOX11 is critical for the proliferation of 
estrogen-receptor negative breast cancer cells
To investigate the role of SOX11 in regulating the 
growth of breast cancer cells, we used siRNA to inhibit 
SOX11 and measure two-dimensional growth in-vitro in 
a panel of ER-negative/HER2-negative (BT20, MDA-
MB-468, HCC70, HCC1937, and MDA-MB-231), 
ER-negative/HER2-positive (SKBr-3, and HCC1954), 
ER-positive/HER2-positive (BT474), and ER-positive/
HER2-negative (MCF7 and ZR751) breast cancer cell 
lines as well as non-transformed breast cell lines (HME-
hTERT and MCF10A). SOX11 knockdown significantly 
reduced growth of each of the ER-negative breast cancer 
cell lines tested, including both HER2-negative and 
HER2-positive, ER-negative cell lines, as well as triple-
negative cell lines representative of the claudin-low 
subtype. (Figure 4A, top rows). Alternatively, SOX11 
knockdown had little to no effect on the growth of ER-
positive breast cancer cells or non-transformed breast cells 
(Figure 4A, lower rows), which are ER-negative, but did 
Figure 3: SOX11 expression and DNA methylation varies between normal breast and different breast cancer subtypes. 
A. SOX11 mRNA expression in normal breast samples and tumors categorized by PAM50 status, plotted as individual values with mean 
and standard deviation of the populations. B. CpG DNA methylation at a site near the 5’ region of SOX11 in normal breast samples and 
breast tumors categorized by PAM50 status plotted as individual values with mean and standard deviation of the populations. Statistical 
significance is indicated by asterisks (****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, ns = not significant).
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Figure 4: SOX11 is critical for growth and proliferation of BLBC cells. A. The effect of siRNA depletion of SOX11 on growth 
of breast cancer and immortalized breast cell lines. Breast cancer cell lines are grouped by ER-status (ER-negtative in top two rows, 
ER-postive in third row) with immortal, non-transformed breast cells in bottom row. B. Colony formation in ER-positive MCF7 and ER-
negative MDA-MB-468 and HCC70 cells following siRNA to luciferase (negative control) or SOX11. C. Immuno-fluorescent images of 
MCF7 (top) and MDA-MB-468 (bottom) following non-targeting siLuc or SOX11 targeted siRNA stained for phosphorylated histone H3. 
Representative images shown with quantification taken from three independent replicates, with summed counts from seven unique fields 
for each sample. * denotes p<0.05.
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not have detectable levels of SOX11 by qPCR (data not 
shown). We also evaluated the effect of SOX11 inhibition 
on anchorage-independent growth and found that siRNA 
knockdown of SOX11 did not inhibit colony formation in 
the ER-positive cell line MCF7 (Figure 4B, left), but did 
significantly inhibit colony formation in ER-negative cell 
lines MDA-MB-468 and HCC70 (Figure 4B, center and 
right). These findings demonstrate that SOX11 is required 
for growth of ER-negative breast cancer cell lines, but is 
not required for growth of ER-positive breast cancer cells, 
or non-transformed breast cell lines.
To evaluate whether loss of SOX11 results in 
decreased proliferation of BLBC, phosphorylated histone 
H3 (pH3), a marker of mitotic cells, was measured in 
MCF7 and MDA-MB-468 cells which had been treated 
with siRNA targeting SOX11 or non-targeting control 
siRNA. SOX11 knockdown did not significantly decrease 
the proportion of pH3-positive cells in MCF7 cells, but 
did have a significant effect, reducing the percent of 
cells which stained positive for phosphorylated Histone 
H3 in MDA-MB-468 cells (Figure 4C), demonstrating 
that loss of SOX11 in BLBC cells reduces proliferation. 
Conversely, SOX11 knockdown did not significantly 
increase apoptosis in BLBC cells as measured by 
Annexin-V flow cytometry (Supplementary Figure S4), 
demonstrating that apoptosis did not contribute to the 
decrease in growth of this cell line.
SOX11 promotes increased migration of breast 
cancer cells
While investigating the role of SOX11 depletion 
in ER-negative breast cancer cells, we noted an altered 
morphology of MDA-MB-231 cells following treatment 
with siRNA targeting SOX11. MDA-MB-231 cells 
typically have a mesenchymal-like appearance with long 
protrusions; however, following SOX11 depletion, the 
cells appear more cuboidal (Supplementary Figure S5, 
upper panel). We therefore investigated whether SOX11 
played a role in maintaining the epithelial-to-mesenchymal 
transition (EMT)-like characteristics associated with 
BLBC [17], including increased motility and invasiveness 
as well as expression of transcription factors previously 
shown to promote EMT-like characteristics.
For these studies, cell migration and invasion of 
breast cancer cell lines MDA-MB-468 and MDA-MB-231 
was measured following siRNA inhibition of SOX11, 
whereas the ER-positive cell line, MCF7, which typically 
demonstrates low levels of motility and invasion, was 
transduced with a viral vector encoding the SOX11 cDNA 
under the control of a tetracycline-inducible promoter 
to produce overexpression of SOX11 upon the addition 
of doxycycline (DOX). The ability of the invasive, ER-
negative breast cancer cells lines to migrate towards 
serum supplemented media either uninhibited (Figure 5A, 
top two rows) or through a matrigel coated membrane 
(Figure 5B, top two rows) was reduced upon knockdown 
of SOX11. A reduction in migration was also seen in other 
ER-negative cell lines: HCC70, HCC1937, and HCC1954 
(Supplementary Figure S5 lower panel). This result 
indicates that SOX11 is critical for the increased motility 
associated with aggressive BLBC cells. Overexpression 
of SOX11 in MCF7 cells significantly increased the 
migratory ability of the cells (Figure 5A, bottom row), and 
caused a small but non-statistically-significant increase 
in the invasiveness of the cells (Figure 5B, bottom row). 
These results suggest that SOX 11 primarily promotes 
promotes the migratory ability of breast cancer cells.
Following SOX11 depletion, ER-negative cells 
exhibited a reduction in the closely related SOX 
transcription factor, SOX4, (Figure 5C, left and center), 
whereas overexpression of SOX11 in MCF7 cells resulted 
in an increase in SOX4 expression (Figure 5C, right). 
SOX4 has been shown to function cooperatively with 
SOX11 during neuronal development [18] and is also a 
regulator of EMT in breast cancer [19]. These findings 
suggest that SOX11 may cooperate with other SOX factors 
and regulators of migration and invasion to promote EMT-
like characteristics associated with aggressive basal-like 
breast tumors.
SOX11 is critical for elevated expression of genes 
that define the basal-like subtype
Breast tumors can be subtyped into BLBC and the 
other molecular subtypes using the Prediction Analysis of 
Microarray 50 (PAM50) test, which analyzes expression of 
50 genes to separate breast tumors into specific subtypes 
[20]. We next investigated whether SOX11 inhibition 
would alter expression of the genes that define the BLBC 
subtype, particularly those genes in the PAM50 test which 
are characteristically high in BLBC tumors. Therefore, the 
expression of several PAM50 genes (FOXC1, CCNE1, 
ANLN, KRT14, SFRP1, MIA, CDCA1, MELK) was 
measured following inhibition of SOX11 (Figure 5D).
In the non-BLBC cell line MCF7, most signature 
BLBC genes tested were either undetectable by qRT-
PCR, or did not change following SOX11 depletion. 
The exception to this was anillin, actin binding protein 
(ANLN), which was reduced in both the MCF7 cell 
line and the BLBC cell line MDA-MB-468 following 
SOX11 depletion. In MDA-MB-468 cells, the majority 
of signature BLBC genes were reduced following 
inhibition of SOX11. This set of genes included 
forkhead box C1 (FOXC1), keratin 14 (KRT14), cyclin 
E1 (CCNE1), melanoma inhibitory activity (MIA) 
and secreted frizzled-related protein 1 (SFRP1), while 
expression of CDCA1 and MELK, (neither of which 
were detectable in MCF7), did not change following 
SOX11 depletion. These results show that SOX11 
regulates the expression of many genes that define 
“basal-ness” in BLBC.
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Figure 5: SOX11 is a critical regulator of migration, invasion, and BLBC gene expression. Representative pictures and 
quantification of the effect of SOX11 siRNA on migration A. and invasion B. for MDA-MB-231 (top row), MDA-MB-468 (middle 
row) and MCF7 cells with DOX inducible SOX11 expression (bottom row). C. Relative mRNA expression of SOX4 in ER-negative 
MDA-MB-468 and HCC70 cells following siRNA knockdown of SOX11 (left and middle) and ER-positive MCF7 cells with DOX-induced 
overexpression of SOX11. D. Relative expression of SOX11 and a sampling of PAM50 genes associated with BLBC following non-
targeting siLuc or SOX11 inhibiting siRNA in MCF7 and MDA-MB-468 cell lines. * denotes p<0.05.
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High SOX11 expression is associated with poor 
survival
We next investigated whether SOX11 is a prognostic 
marker in women with breast cancer by performing 
survival analyses using multiple available datasets as 
described in Materials and Methods. This analysis showed 
that high SOX11 expression is significantly associated 
with poor disease-specific, overall, recurrence-free, and 
metastasis-free survival in multiple breast cancer datasets 
(Figure 6A and Supplementary Figure S6). As ER status 
is known to be strongly correlated with breast cancer 
survival, we used the Curtis dataset, which had the most 
patients with follow-up survival data, to also examine 
the correlation of SOX11 with survival among patients 
after stratifying by ER or HER2 status. In analyses of 
overall survival (Supplementary Figure S6), high SOX11 
was associated with worse prognosis for patients with 
either ER-negative or ER-positive tumors and was also 
correlated with poor survival regardless of HER2 status. 
Using disease-specific survival outcome (Figure 6F–6J), 
high SOX11 was suggestive of worse disease-free survival 
in ER-negative patients (Figure 6H), but this result only 
trended toward significance (p=0.0775), and was most 
likely due to the small sample size of patients with ER-
negative breast cancer available for the disease specific 
survival analysis. While SOX11 levels are comparatively 
low in ER-positive tumors (Figure 2A), ER-positive 
tumors with higher than median SOX11 expression 
have a significantly worse prognosis. High SOX11 
expression also correlated with poor disease-specific 
survival regardless of HER2 status. These results suggest 
that though SOX11 is typically more highly expressed 
in basal-like and HER2-positive breast cancer, it likely 
functions in other breast cancer subtypes to promote the 
growth of aggressive, poor-prognosis tumors. To formally 
determine the prognostic value of SOX11 expression in 
breast cancer survival, a multivariate Cox proportional 
hazards analysis including SOX11 expression, tumor size, 
grade, node status, and PAM50 subtype was utilized and 
demonstrated that SOX11 expression is an independent 
prognostic indicator for increased risk of breast cancer 
related death (Table 2).
DISCUSSION
In this study we used a novel screening approach 
integrating RNA, DNA and protein data to identify 
transcription factors which are highly expressed and active 
in BLBC. For this study, we focused on transcription 
factors which were critical for growth in BLBC cell lines 
and identified 8 transcription factors that were critical for 
the growth of BLBC. One of these transcription factors, 
SOX11, is a novel regulator of BLBC growth which 
regulates multiple BLBC phenotypes, including migration, 
invasion, and expression of genes highly expressed in 
BLBC tumors. Furthermore, we found that high SOX11 
expression is associated with poor breast cancer patient 
survival. Therefore, our studies demonstrate that SOX11 
may be a master regulator of the BLBC subtype and a 
novel target for the treatment of this aggressive disease.
Each of the assays in the primary screen identified 
transcription factors potentially involved in regulating 
critical processes in BLBC cells. Among these are 
several transcription factors previously described as 
highly expressed in BLBC or TNBC, including FOXC1 
[21], EZH2 [22], and ELF5 [23], (identified in our 
mRNA expression analysis); MYC [3, 10], E2F factors 
[24], and HIF1/ARNT [3, 25] (identified in our DNA 
promoter sequence analysis); and AP-1 [26] and NF-kB 
[27] (identified in our protein DNA-binding assay). The 
identification of these transcription factors known to be 
highly expressed in BLBC serves to demonstrate the 
validity of our screen.
Focusing this study on transcription factors critical 
for growth excluded the two transcription factors which 
were discovered by all three screens, PPARα and STAT1. 
While our study indicates that PPARα and STAT1 are 
not essential for BLBC growth, these factors may be 
critical in the development and maintenance of other 
BLBC phenotypes. PPAR transcription factors are known 
regulators of lipid and fatty acid metabolism (reviewed 
in [28]), and understanding the role of PPARα in BLBC 
may require investigation of lipid metabolism within 
mammary epithelial cells as well as in conjunction with 
adjacent adipocytes. The role of STAT1 in breast cancer is 
not fully understood, with studies suggesting both tumor 
suppressing [29], and tumor promoting activities [30]. 
Indeed, loss of STAT1 in mice results in spontaneous 
development of ER-positive breast tumors [31], whereas 
expression of STAT1 was found to be increased in node-
positive TNBC compared to node-negative TNBC. These 
results suggest that STAT1 may act as a tumor suppressor 
in ER-positive breast cancer cells, but may promote 
invasiveness of TNBCs.
We identified 8 transcription factors for which 
siRNA inhibition reduced growth in multiple BLBC cell 
lines in our secondary screen. Of these, only SOX11 
was required for growth of all 3 BLBC cell lines, but 
not for the growth of the non-BLBC cell lines. SOX11 
is a member of the SOX (SRY-related HMG-box) family 
of transcription factors. Other members of this family, 
including SOX9 [32], SOX10 [33], and SOX4 [19], have 
been shown to be important regulators of mammary stem 
cells and EMT; whereas, fewer studies have evaluated the 
role of SOX11 in normal or malignant breast cells. SOX11 
has been previously shown to be highly expressed in 
embryonic mammary bud epithelial cells [34], and SOX11 
was elevated in BRCA-/- mammary epithelium compared 
to mammary epithelium in normal postnatal mice [34]. 
The role of SOX11 in other cancers has been particularly 
dependent on cancer type, with reports suggesting both 
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oncogenic and tumor suppressor roles. In mantle cell 
lymphoma (MCL) SOX11 is highly expressed and is a 
diagnostic biomarker that distinguishes MCL from other 
mature B-cell lymphomas [35]. Further study of SOX11 
in MCL cells has demonstrated that high SOX11 promotes 
the growth of lymphoma cells and prevents differentiation 
[36]. However, in other cancer types, including other 
hematological cancers, and epithelial ovarian cancer, 
SOX11 is frequently methylated and high SOX11 
expression is associated with improved survival [16, 37–
39]. Our results demonstrate that SOX11 is differentially 
expressed in breast cancer subtypes and is required for the 
growth of transformed ER-negative breast cancer cells, 
but not for the growth of ER-positive cancer cells or non-
transformed breast cells. These results indicate that the 
role of SOX11 needs to be considered within specific cell 
and cancer types.
Several studies have shown that SOX11 can regulate 
differentiation. In MCL and in osteoblasts, SOX11 
promotes proliferation of progenitor cells and blocks 
terminal differentiation [36, 40]. Our findings suggest 
that SOX11 may serve a similar role in BLBC, promoting 
growth, preserving migratory and invasive characteristics 
associated with less differentiated breast cells, and 
preventing differentiation to luminal cells. Additionally, 
SOX11 and other members of the SOXC group, have 
been shown to be required for survival of progenitor cells 
during organogenesis [41]. Therefore, the role of SOX11 
in breast development and differentiation is an important 
subject for future investigation.
Our results demonstrating that SOX11 inhibition 
affected multiple BLBC phenotypes suggest that SOX11 
acts as a key signaling molecule in these breast cancers. 
This theory is supported by our finding that several PAM50 
Figure 6: High SOX11 associates with poor prognosis. Survival data from the Curtis dataset [50] investigating overall survival 
in all patients A. or subsets of patients based on ER-status B–C. or HER2 status D–E. with patients dichotomized by the median SOX11 
expression level within each analysis. Equivalent studies of breast cancer-specific survival for all patients F. or subsets based on ER-status 
G–H. and HER2 status I–J. were also performed.
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markers of BLBC, including the FOXC1 transcription factor, 
are reduced following SOX11 inhibition. High FOXC1 
mRNA expression is frequently seen in BLBCs [21]. FOXC1 
has been shown to be enriched in mammary progenitor cells 
[42], and its reduction in response to SOX11 inhibition in 
BLBC may be critical for the shift towards the BLBC 
phenotype.
Our results showed that high SOX11 expression is 
correlated with worse clinical outcome in breast cancer 
patients. However, other studies in ovarian cancer [37] and 
in gastric cancer [43] have found that elevated SOX11 is 
associated with improved outcome, and that SOX11 can 
act as a tumor suppressor. These findings demonstrate 
that the roles of SOX11 are likely to be dependent on the 
context of the tumor and cell type. In breast cancers, one 
group has recently shown that high grade breast tumors 
had lower levels of nuclear SOX11 protein, and that 
nuclear SOX11 was associated with improved clinical 
outcome [44]. Our results reported here combined with 
these previous studies support further evaluation of the 
role and clinical significance of SOX11.
For this study we used a novel, comprehensive, and 
integrated approach utilizing RNA-, DNA- and protein-
based assays to identify a set transcription factors that are 
differentially activated in BLBC and may be critical for 
BLBC development and progression. The discovery that 
SOX11 is critical for the growth, migration, and invasion of 
BLBC cells identifies a novel molecule that can be targeted 
for the treatment of BLBC. Further study of SOX11 and the 
other transcription factors identified here will be essential 
to understanding their role controlling BLBC growth 
and tumorigenicity. Such studies will provide additional 
therapeutic targets to effectively treat this aggressive form of 
breast cancer.
MATERIALS AND METHODS
Cell lines
Breast cancer cell lines were purchased from 
American Type Culture Collection (ATCC, Manassas, 
VA) and their identities were confirmed by short tandem 
repeat (STR) DNA fingerprinting using the AmpFℓSTR 
Identifiler kit (cat# 4322288, Life Technologies, Foster 
City, CA). as described previously [45]. Cells were 
maintained according to ATCC recommendations.
RNA expression of transcription factors in 
TNBC and non-TNBC
Expression of 702 genes previously identified 
as DNA-binding transcriptional regulators [5] was 
compared using OncomineTM (oncomine.com, 
Compendia Bioscience, Ann Arbor, MI) to perform a 
Table 2: High SOX11 is an independent prognostic factor associated with increased risk of breast cancer caused 
death
Disease-Specific Survival - Curtis Dataset
n HR (conf. int) p-value
SOX11 Low 996 Reference
SOX11 High 996 1.42 (1.17-1.73) 0.00052
Tumor Size 1.01 (1.01-1.02) <0.00001
Grade 1 170 Reference
Grade 2 775 1.54 (0.94-2.54) 0.08609
Grade 3 957 1.69 (1.03-2.79) 0.03852
Grade NA 90
Lymph neg 1042 Reference
Lymph pos 950 2.22 (1.83-2.69) <0.00001
Luminal A 721 Reference
Luminal B 492 2.04 (1.57-2.64) <0.00001
Normal-like 202 1.71 (1.18-2.46) 0.00456
HER2 240 2.21 (1.63-3.00) <0.00001
Basal-like 331 1.84 (1.35-2.51) 0.00011
Not classified 6
Multivariate Cox proportional hazards model of the risk associated with high SOX11 expression on disease- specific 
survival in Curtis Dataset [50], including tumor size, grade, lymph node status and breast cancer subtype.
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meta-analysis of differential expression between TNBC 
and non-TNBC across 15 breast tumor datasets which 
contain TNBC status annotation (listed in Supplementary 
Table S1). Differential gene expression analysis was 
performed for each dataset, with all genes ranked by 
significance (p-value) for higher expression in TNBC 
vs. non-TNBC tumors. The p-values for each dataset are 
shown using a colorimetric scale in Figure 1D. The p-
value of the dataset showing the median gene rank across 
all datasets is shown on the right in the column labeled 
“Median Rank p-value.” The median gene rank and 
associated p-value across the set of 15 datasets for each 
investigated transcription factor was then used to select 
candidate transcription factors which had increased 
expression in TNBC with a cutoff of p<0.05.
DNA Cis-element promoter analysis
mRNA expression and tumor subtype classifications 
from three previously published breast tumor microarray 
studies [6–8] were used to select genes consistently more 
highly expressed in BLBC compared to non-BLBC. From 
each dataset, we selected the genes with higher expression 
and a univariate p-value <0.01 in BLBC tumors compared 
to non-BLBC tumors. The intersection of the three 
resulting sets gave a 117-gene BLBC gene set. A set of 
1500 control genes were randomly selected from the set 
of genes not significantly more highly expressed in BLBC 
tumors. The online tool, CORE_TF [9], was then used 
for cis-element recognition using binding matrices from 
TransFac 11.2 (Biobase, Beverly, MA) [46] in the region 
from -1 kb through exon 1 of each gene. The frequency of 
motif occurrence among the 117 BLBC gene promoters 
was compared to that of the same region in control gene 
promoters to identify response elements significantly 
enriched in genes highly expressed in BLBC. An exact 
binomial test with a cutoff of p<0.05 was used for 
significance.
Transcription factor protein DNA-binding assay
Nuclear proteins were collected from breast cancer 
cell lines using the NE-PER kit (Thermo Scientific, 
Rockford, IL). The protein DNA-binding assay was 
performed using the Combo Protein/DNA Array 
(Affymetrix cat# MA1215, Santa Clara, CA) according 
to manufacturer instructions. Briefly, 10ug of nuclear 
protein was combined with biotin-labeled DNA probe 
mix representing 345 consensus binding motifs. After 
incubation, the protein/probe mixture was put through 
spin columns to remove unbound probes. The protein/
probe mixture was heat denatured, and the previously 
bound probes were hybridized to membranes containing 
corresponding consensus transcription factor binding 
motifs. Detection was performed with streptavidin-HRP 
using BioRad ChemiDoc. TIF images were quantified 
using ImageJ Dot Blot Analyzer (available in IJ macros 
toolsets repertory at http://rsb.info.nih.gov/ij/macros/
toolsets/DotBlotAnalyzer.txt), with the intensity of each 
spot calculated relative to TFIID. The experiment was 
performed in triplicate for each cell line. The BLBC 
average (relative intensity of each spot averaged across 
each of the triplicate values for HCC1143, HCC1937, 
BT20, and MDA468) and the luminal average (relative 
intensity averaged across each replicate for T47D, MCF7, 
BT474, and ZR751) were calculated and compared using 
the Student’s t-test. Spots which had a fold change greater 
than 1.4 and with a p-value less than 0.05 were included 
for follow up.
Integration of DNA promoter, RNA expression 
and protein DNA-binding assays
For the promoter analysis and the protein DNA-
binding analyses which result in transcription factor motifs, 
we used TRANSFAC [46] annotation and published 
literature to identify transcription factors which recognize 
the identified motifs and specific genes which compose the 
resulting transcription factors. The set of genes resulting 
from each assay were compared and we selected the set of 
33 genes which were identified in at least 2 of the 3 assays.
siRNA, quantitative real-time polymerase chain 
reaction (qPCR) and growth, migration and 
invasion assays
siRNA, qPCR and growth assays were performed as 
previously described [47]. qPCR sequences are listed in 
Supplementary Table S6. Migration and invasion assays 
were performed as previously reported [48], allowing 18 
hours for migration, after which passed cells were stained 
(Hema 3 System, Fischer Scientific #22-122911) and five 
20x fields counted.
Phospho-histone H3 immunofluorescence
The phospho-histone H3 immunofluorescence assay 
was performed as previously described [49] with primary 
anti-phoshpo-histone H3 (Cell Signaling #3377) and 
secondary Alexa Fluor 594 conjugated anti-rabbit (Life 
Technologies #A-11037) antibodies. Nuclei were stained 
with 4',6-diamidino-2-phenylindole (DAPI). Images were 
acquired using a Nikon Eclipse Ti microscope with NIS 
Elements imaging software (Nikon, Melville, NY).
Analysis of survival in breast cancer datasets
mRNA expression and survival data from Curtis et 
al. [50], Desmedt et al. [51], Esserman et al. [52], and 
Hatzis et al. [53] were used to evaluate the prognostic 
importance of SOX11. Data obtained from the Oncomine 
database were analyzed using R statistical software 
to generate Kaplan–Meier survival curves, determine 
statistical significance using the log rank (Mantel–Cox) 
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method, and conduct Cox proportional hazards models 
analyses. Expression data was dichotomized at the mean 
expression level.
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